Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Products under Development by Stage of Development | 8 | 1 |
| Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Products under Development by Therapy Area | 9 | 1 |
| Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Products under Development by Indication | 10 | 1 |
| Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Products under Development by Companies | 13 | 2 |
| Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Products under Development by Universities/Institutes | 15 | 2 |
| Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Therapeutics Assessment | 17 | 4 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Route of Administration | 18 | 1 |
| Assessment by Molecule Type | 19 | 2 |
| Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Companies Involved in Therapeutics Development | 21 | 6 |
| Advaxis, Inc. | 21 | 1 |
| Akshaya Bio Inc. | 22 | 1 |
| Celgene Corporation | 23 | 1 |
| Etubics Corporation | 24 | 1 |
| OSE Immunotherapeutics | 25 | 1 |
| Vaxon Biotech | 26 | 1 |
| Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Drug Profiles | 27 | 14 |
| ETBX-011 Drug Profile | 27 | 3 |
| GI-6207 Drug Profile | 30 | 2 |
| OSE-2101 Drug Profile | 32 | 3 |
| Peptides to Activate CEACAM5 for Crohn's Disease Drug Profile | 35 | 1 |
| Vaccine to Target CEA for Oncology Drug Profile | 36 | 1 |
| Vaccine to Target CEA for Ovarian Cancer Drug Profile | 37 | 2 |
| Vbx-016 Drug Profile | 39 | 1 |
| Vbx-026 Drug Profile | 40 | 1 |
| Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Dormant Projects | 41 | 1 |
| Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Discontinued Products | 42 | 1 |
| Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Featured News &Press Releases | 43 | 10 |
| Feb 22, 2016: First patients enrolled and dosed in the pivotal trial of Phase 3 of the immunotherapy Tedopi for advanced non-small cell lung cancer | 43 | 1 |
| Feb 04, 2016: OSE Pharma Announces U.S. Initiation of Atalante 1, the Company s Global, Pivotal Phase 3 Trial for Tedopi Immunotherapy in Non-Small Cell Lung Cancer | 43 | 1 |
| Jan 06, 2016: OSE Pharma Announces Initiation of Its Pivotal Phase 3 Trial of Tedopi in Non-Small Cell Lung Cancer | 44 | 1 |
| Sep 29, 2015: OSE Pharma to participate to the Large &Midcap Event in Paris on October 7-8, 2015 | 45 | 1 |
| Aug 05, 2015: Etubics Platform Shown to Significantly Increase Survival Of End Stage Colorectal Cancer Patients | 45 | 1 |
| Jun 22, 2015: Vaxon Biotech granted Japanese patent for new cancer vaccine candidates | 46 | 1 |
| May 28, 2015: OSE Pharma and Simbec- Orion to participate in the 51st annual Meeting of the American Society of Clinical Oncology, May 29th to June 2nd 2015, Chicago | 47 | 1 |
| Jan 29, 2015: OSE Pharma appoints Simbec-Orion to conduct its Tedopi Phase III international clinical trial in advanced lung cancer patients | 47 | 1 |
| Sep 15, 2014: Texopi, a new ray of hope for lung cancer immunotherapy | 48 | 1 |
| Jun 23, 2014: Agreement on Phase 3 Trial Protocol of OSE Pharma's OSE-2101 From the FDA and EMA | 49 | 1 |
| May 28, 2014: Etubics Will Present Results of Its Colorectal Cancer Phase 1 and 2 Immunotherapy Trial at the Annual American Society of Clinical Oncology Meeting in Chicago | 50 | 1 |
| Jun 04, 2013: OSE Pharma Announces A Grant From OSEO For Its Targeted Cancer Immune Therapy In Phase III | 50 | 1 |
| May 06, 2013: Etubics Platform Generates Solid Immune Response In Colorectal Cancer Patients | 51 | 1 |
| Apr 03, 2013: GlobeImmune Initiates Phase II Study Of New T Cell Stimulating Cancer Vaccine Targeting CEA In Patients With Metastatic Medullary Thyroid Cancer | 52 | 1 |
| Feb 14, 2013: OSE Pharma Announces The Orphan Drug Status Granted In The US For OSE 2101 | 52 | 1 |
| Appendix | 53 | 2 |
| Methodology | 53 | 1 |
| Coverage | 53 | 1 |
| Secondary Research | 53 | 1 |
| Primary Research | 53 | 1 |
| Expert Panel Validation | 53 | 1 |
| Contact Us | 53 | 1 |
| Disclaimer | 54 | 1 |